Next Article in Journal
Medication-Focused Patient Counseling Upon Discharge: A Feasibility Study of Effect on Patient Satisfaction
Previous Article in Journal
Checking Inhaler Technique in the Community Pharmacy: Predictors of Critical Errors
Previous Article in Special Issue
Using Community Pharmacy Immunization Screening Forms to Identify Potential Immunization Opportunities
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.
Article

The Impact of Pharmacist Vaccination Privilege during a Nation-Wide Measles Outbreak

Walgreen Co., Deerfield, IL 60012, USA
*
Author to whom correspondence should be addressed.
Pharmacy 2020, 8(1), 7; https://doi.org/10.3390/pharmacy8010007
Received: 31 October 2019 / Revised: 31 December 2019 / Accepted: 6 January 2020 / Published: 9 January 2020
(This article belongs to the Special Issue Pharmacy-based Immunization Services)
The 2019 measles outbreak was the worst since the USA eliminated measles in 2000. This paper presents the vaccination trends for a large chain-pharmacy, Walgreens, and examines the estimated vaccination capacity and impact of pharmacist privilege policies across states. Specifically, we estimated the number of people who could have been vaccinated in eight states with reduced or no measles, mumps, and rubella (MMR) vaccination privilege during the study period January–June, 2019. During the study period, Walgreens pharmacists administered MMR vaccines to 62,526 patients, a 231.9% increase. If pharmacists had been permitted to vaccinate against measles in the eight states investigated, Walgreens pharmacies would have administered between 12,404 and 36,551 additional vaccinations during that time. We also estimated all chain pharmacies’ capacity to vaccinate in one state that was severely impacted by the measles outbreak, New York, using a range from normal pharmacy operating conditions to maximum capacity. Assuming sufficient demand, it was estimated that chain pharmacies in New York State would have the capacity to vaccinate between 47,688 and 174,856 patients daily, achieving MMR vaccination (first dose) of the measles-susceptible population within 8–28 days. Overall, this study demonstrates the public health value of pharmacist vaccination privilege during a nation-wide outbreak of measles. View Full-Text
Keywords: measles; MMR vaccine; pharmacist vaccination privilege; policy; outbreak; pharmacy; vaccine hesitancy measles; MMR vaccine; pharmacist vaccination privilege; policy; outbreak; pharmacy; vaccine hesitancy
Show Figures

Figure 1

MDPI and ACS Style

Singh, T.; Smith-Ray, R.L.; Taitel, M. The Impact of Pharmacist Vaccination Privilege during a Nation-Wide Measles Outbreak. Pharmacy 2020, 8, 7. https://doi.org/10.3390/pharmacy8010007

AMA Style

Singh T, Smith-Ray RL, Taitel M. The Impact of Pharmacist Vaccination Privilege during a Nation-Wide Measles Outbreak. Pharmacy. 2020; 8(1):7. https://doi.org/10.3390/pharmacy8010007

Chicago/Turabian Style

Singh, Tanya, Renae L. Smith-Ray, and Michael Taitel. 2020. "The Impact of Pharmacist Vaccination Privilege during a Nation-Wide Measles Outbreak" Pharmacy 8, no. 1: 7. https://doi.org/10.3390/pharmacy8010007

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop